Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Colorcon
US Department of Justice
Daiichi Sankyo
McKesson
Cipla
Federal Trade Commission
Merck
Novartis
Citi

Generated: February 20, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,957,079

« Back to Dashboard

Summary for Patent: 8,957,079
Title:Inhibitors of Bruton's tyrosine kinase
Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk, such as those having the structure: ##STR00001## Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
Inventor(s): Honigberg; Lee (San Francisco, CA), Verner; Erik (Belmont, CA), Pan; Zhengying (Austin, TX)
Assignee: Pharmacyclics, Inc. (Sunnyvale, CA)
Application Number:13/654,173
Patent Claim Types:
see list of patent claims
Compound; Composition; Dosage form;

Drugs Protected by US Patent 8,957,079

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Pharmacyclics Inc IMBRUVICA ibrutinib CAPSULE;ORAL 205552-002 Dec 20, 2017 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Pharmacyclics Inc IMBRUVICA ibrutinib CAPSULE;ORAL 205552-001 Nov 13, 2013 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,957,079

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,759,516 Inhibitors of Bruton's tyrosine kinase ➤ Try a Free Trial
8,552,010 Inhibitors of Bruton'S tyrosine kinase ➤ Try a Free Trial
8,697,711 Inhibitors of bruton'S tyrosine kinase ➤ Try a Free Trial
7,514,444 Inhibitors of bruton's tyrosine kinase ➤ Try a Free Trial
9,139,591 Inhibitors of bruton's tyrosine kinase ➤ Try a Free Trial
7,960,396 Inhibitors of Bruton's tyrosine kinase ➤ Try a Free Trial
8,236,812 Inhibitors of bruton's tyrosine kinase ➤ Try a Free Trial
8,741,908 Inhibitors of bruton's tyrosine kinase ➤ Try a Free Trial
9,133,198 Inhibitors of bruton'S tyrosine kinase ➤ Try a Free Trial
8,703,780 Inhibitors of Bruton's tyrosine kinase ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,957,079

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Slovenia 2530083 ➤ Try a Free Trial
Slovenia 2529621 ➤ Try a Free Trial
Slovenia 2526934 ➤ Try a Free Trial
Slovenia 2526933 ➤ Try a Free Trial
Slovenia 2526771 ➤ Try a Free Trial
Slovenia 2201840 ➤ Try a Free Trial
Slovenia 2081435 ➤ Try a Free Trial
Singapore 10201508035T ➤ Try a Free Trial
Singapore 10201503235V ➤ Try a Free Trial
Singapore 166093 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Chubb
AstraZeneca
Johnson and Johnson
Accenture
McKesson
Argus Health
McKinsey
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot